Biocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor inhibitor for various ophthalmology conditions, including age-related macular degeneration. Yesafili is similar to Eylea. CEO Shreehas Tambe highlighted the company's milestone in bringing interchangeable insulin and biosimilars to patients. The approval comes as 19.8 million Americans live with macular degeneration, with aflibercept sales reaching $5.89 billion in 2023. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
